Publication: Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis
| dc.contributor.author | KARAALP, ATİLA | |
| dc.contributor.author | SÜSLEYİCİ, BELGİN | |
| dc.contributor.authors | Cevik M., Namal E., Iner-Koksal U., Dinc-Sener N., KARAALP A., Ciftci C., SÜSLEYİCİ B. | |
| dc.date.accessioned | 2023-02-13T13:06:12Z | |
| dc.date.accessioned | 2026-01-10T20:30:57Z | |
| dc.date.available | 2023-02-13T13:06:12Z | |
| dc.date.issued | 2022-03-01 | |
| dc.description.abstract | Background Programmed Cell Death-1 (PD-1) together with Programmed Death Ligand 1 (PDL-1) have crucial roles in anti-tumor immune response, cancer susceptibility and prognosis. Since PD-1 and PDL-1 have been considered as important genetic risk factors in cancer development and their functions can be affected by polymorphic sites, we investigated the effects of PD-1 rs2227981, rs2227982, rs36084323 and PDL-1 rs2282055, rs822336 gene polymorphisms on colorectal cancer (CRC) risk and prognosis in Turkish subjects. Methods and results Our study group consisted of 5-FU or Capacitabine prescribed CRC diagnosed patients and healthy controls. Genotype analyses of PD1 and PDL-1 polymorphisms were performed with Agena MassARRAY platform. rs36084323 CT genotype frequency was found to be higher in controls compared to cases (p C polymorphism might be useful in predicting CRC prognosis. PDL-1 rs2282055 T > G polymorphism might be useful in predicting both CRC risk and prognosis. Further studies should be conducted in larger and different populations to clear the roles of PD-1 and PDL-1 polymorphisms in CRC risk and prognosis. | |
| dc.identifier.citation | Cevik M., Namal E., Iner-Koksal U., Dinc-Sener N., KARAALP A., Ciftci C., SÜSLEYİCİ B., "Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis", MOLECULAR BIOLOGY REPORTS, cilt.49, sa.3, ss.1827-1836, 2022 | |
| dc.identifier.doi | 10.1007/s11033-021-06992-9 | |
| dc.identifier.endpage | 1836 | |
| dc.identifier.issn | 0301-4851 | |
| dc.identifier.issue | 3 | |
| dc.identifier.startpage | 1827 | |
| dc.identifier.uri | https://hdl.handle.net/11424/286140 | |
| dc.identifier.volume | 49 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | MOLECULAR BIOLOGY REPORTS | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Moleküler Biyoloji ve Genetik | |
| dc.subject | Sitogenetik | |
| dc.subject | Temel Bilimler | |
| dc.subject | Life Sciences | |
| dc.subject | Molecular Biology and Genetics | |
| dc.subject | Cytogenetic | |
| dc.subject | Natural Sciences | |
| dc.subject | BİYOKİMYA VE MOLEKÜLER BİYOLOJİ | |
| dc.subject | Moleküler Biyoloji ve Genetik | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | BIOCHEMISTRY & MOLECULAR BIOLOGY | |
| dc.subject | MOLECULAR BIOLOGY & GENETICS | |
| dc.subject | Life Sciences (LIFE) | |
| dc.subject | Biochemistry, Genetics and Molecular Biology (miscellaneous) | |
| dc.subject | Clinical Biochemistry | |
| dc.subject | Cancer Research | |
| dc.subject | Molecular Biology | |
| dc.subject | Drug Discovery | |
| dc.subject | Aging | |
| dc.subject | General Biochemistry, Genetics and Molecular Biology | |
| dc.subject | Biochemistry | |
| dc.subject | Structural Biology | |
| dc.subject | Colorectal cancer | |
| dc.subject | Immune check point | |
| dc.subject | PD-1 | |
| dc.subject | PDL-1 | |
| dc.subject | rs36084323 | |
| dc.subject | rs822336 | |
| dc.subject | rs2282055 | |
| dc.subject | CELL LUNG-CANCER | |
| dc.subject | INDUCED EXPRESSION | |
| dc.subject | IMMUNE ESCAPE | |
| dc.subject | BREAST-CANCER | |
| dc.subject | TUMOR-CELLS | |
| dc.subject | PD1 GENE | |
| dc.subject | SUSCEPTIBILITY | |
| dc.subject | PD-1/PD-L1 | |
| dc.subject | CHILDREN | |
| dc.subject | PATHWAY | |
| dc.title | Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis | |
| dc.type | article | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
